Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Back to analysts list

Analyst

Andy Wittmann

Robert W. Baird · covers Industrials, Basic Materials

Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q3 (9 quarters).

Questions
28on tracked calls
Challenge rate
14%4 of 28 questions
Companies
3questioned at least once
Reporting periods
9with questions

These figures cover the whole profile: every tracked question, all reporting periods.

How to read these numbers

Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.

Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.

No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.

Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.

Small samples. Profiles with fewer than 10 questions are marked Limited sample.

Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.

Questions asked

Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.

Showing 28 of 28 questions from 3 companies

JJacobs Solutions15 questions · 8 reporting periods · 4 of 15 challenging
J company page →

Calendar 2026 Q2

what should the investment community expect in terms of income statement adjustments between GAAP and non-GAAP

Guidance ReliabilityM&ATranscript · FY2026 Q3 →
Show response

Venk said the Q3 GAAP/non-GAAP EPS gap was mainly a tax item and, with M&A off the table, the two measures should converge substantially from Q4.

Calendar 2026 Q1

because you mentioned that there was going to be a fiscal third quarter cash outflow in addition to the substantial cash outflow

M&ACapital AllocationTranscript · FY2026 Q2 →
Show response

Nathamuni detailed PA transaction charges: $235M compensation expense acceleration in Q2 (P&L and cash), $105M employee benefit trust payments in Q3 (cash only, already in P&L). Restructuring costs declining substantially in FY2026 versus FY2025.

if those out-year drivers are any different from the ones that you've been realizing here over these last 2 very strong years

Show response

Nathamuni confirmed margin initiatives well underway with global delivery increasing in pace, scope, and scale. AI deployment in enterprise functions providing leverage without raising CapEx (maintained at 1% of revenue) through reallocation from traditional SaaS to AI investments.

Calendar 2025 Q4

the math that I get here from the multiple is substantially larger than the 13 times

Show response

Nathamuni and Subin explained the gap between accounting and economic ownership due to employee benefit trust c-shares, clarifying 40% stake acquired at 13x EBITDA (12.3x including synergies), with NCI reduced by after-tax amount creating apparent multiple discrepancy.

I'd wanna ask about how you're managing the risk criteria here

Cost PressureCompetitive DynamicsTranscript · FY2026 Q1 →
Show response

Pragada confirmed risk profile unchanged from 20-year EPCM delivery model used in life sciences and water, with same flow-through approach to supply chain on current awards.

Calendar 2025 Q3

it is under the 100% targets. And I was wondering what the items in the '26 outlook are that bridge you

ChallengingCapital AllocationMarginTranscript · FY2025 Q4 →
Show response

Nathamuni explained FY2026 FCF guidance includes a one-time tax event unrelated to continuing operations and expected cash expenses from PA acquisition resolution, while underlying cash flow efficiency continues improving.

what was it about the environmental side that caused a little bit of softness? Would you tie that to anything?

Regulation PolicyDemandTranscript · FY2025 Q4 →
Show response

Pragada identified three drivers: regulatory volatility causing private sector client pullbacks among large industrials and chemical companies, FEMA disaster relief funding transfer from federal to state level creating award delays, and a one-time prior-year comp from a federal agency outside the US.

Calendar 2025 Q2

the puts and takes associated with the One Big Beautiful bill here. Obviously, there's a lot of new policy

Regulation PolicyDemandTranscript · FY2025 Q3 →
Show response

Pragada identified positives: DoD infrastructure, FAA opportunities, reshoring backstop. Potential take: Medicaid cuts impacting state/local budgets, but clients not raising this yet.

update us on where you are seeing the onetime costs associated with the split?

Cost PressureMarginTranscript · FY2025 Q3 →
Show response

Nathamuni confirmed on track for $75-95M restructuring in FY2025 (down ~3x from prior year), expecting further dramatic decline in FY2026.

Calendar 2025 Q1

help us understand how you get to the 100% greater than 100% conversion this year in terms of the quarterly cadence?

Capital AllocationMarginTranscript · FY2025 Q2 →
Show response

Nathamuni confirmed substantial Q3 cash flow step-up, not solely Q4-loaded, driven by seasonal patterns and lower cash tax payments.

discuss where your utilizations rate -- your utilization rates stand this year as compared to last year

MarginCompetitive DynamicsTranscript · FY2025 Q2 →
Show response

Pragada noted utilization dipped in January from holiday spillover but has recovered and is exceeding prior quarters in early Q3 as large project backlogs enter production phases.

Calendar 2024 Q4

is the focus on TTM, a reflection of like the next couple of quarters of awards that, maybe are a little bit softer

ChallengingDemandRevenue GrowthTranscript · FY2025 Q1 →
Show response

Pragada explained TTM smooths lumpy large project wins; 19% backlog growth and double-digit growth for several consecutive quarters demonstrate underlying strength.

Is that right, right now, are you losing on a GAAP basis, $4 million on the TSA?

Show response

Nathamuni confirmed TSA is profitable and its expiration represents a margin opportunity, not a headwind.

Calendar 2024 Q3

as you look at '26, do you feel like '26 is the year that we get pretty clean results?

Show response

Pragada confirmed FY2026 will have clean results, with restructuring costs decaying significantly in the second half of FY2025.

your backlog is up 22.5% year-over-year, which is great. But your revenue guidance is up, mid to high-single digits. That seems like a really wide gap

ChallengingDemandRevenue GrowthTranscript · FY2024 Q4 →
Show response

Pragada explained the gap is due to multiyear project duration, not margin dilution, and confirmed large bookings are at or above corporate margins.

CTASCintas8 questions · 4 reporting periods · 0 of 8 challenging
CTAS company page →

Calendar 2026 Q3

You're guiding your net interest expense increasing for the year

Capital AllocationM&ATranscript · FY2027 Q1 →
Show response

Scott explained bridge-loan financing fees (~$6 million over 18 months, about $4 million in FY2027) hit net interest expense; the $103 million guide is unchanged for Q2 to Q4.

I just wanted to ask my follow-up on the FIRE segment and the implementation of the SAP system.

MarginInnovation & R&DTranscript · FY2027 Q1 →
Show response

Jim said SAP is still in pilot in Fire Protection, not yet live, with rollout expected during the fiscal year; it is not affecting guidance or results.

Calendar 2025 Q4

Maybe, Todd, you could just talk about kind of the funnel here. Do you feel like thinking about the amount of capital deployment last year is again doable this year with the progress that you made ...

M&ACapital AllocationTranscript · FY2026 Q2 →
Show response

Strong Q2 capital allocation: $100M+ CapEx, $85M M&A across all 3 route-based businesses, $182M dividends, $600M+ buybacks. M&A unpredictable but pipeline actively managed with decades-old relationships.

over the last couple of years, you've had some competitors that have really gone on volume chasing spree. You guys have obviously executed very well amongst all this, but I was just wondering what ...

Competitive DynamicsPricingTranscript · FY2026 Q2 →
Show response

Competitive environment unchanged. Focus on no-programmer conversion, not competitor wins. Retention at all-time highs. Over 2/3 of new customers from no-programmer market.

Calendar 2025 Q3

do you think that fiscal '26 is a higher investment year in some of these things like route leadership, management trainees, technology than it was in 2025

MarginCapex InvestmentTranscript · FY2026 Q1 →
Show response

More timing than step-up in investment level. Heavier investment began in Q4 FY2025, continuing into FY2026. Outlook for First Aid business remains very positive.

On the First Aid segment gross margins, they were down a decent amount year-over-year. And I was wondering if you could help us understand what either happened this quarter that caused them to be d...

Show response

First Aid gross margin flat sequentially despite tough YoY comp. Investments in route capacity, leadership bench, technology, and selling resources. Timing issue, not structural.

Calendar 2024 Q4

it kind of feels like there's been more national account business that's kind of hit the market and its traded hands

Competitive DynamicsTranscript · FY2025 Q2 →
Show response

CEO deflected from national accounts, pivoting to growth via no-programmer new business. Said focus is expanding the pie rather than competing for share.

could you just talk about any categories in particular? Obviously, you called out the energy, always call it the energy, but maybe other key categories

MarginCost PressureTranscript · FY2025 Q2 →
Show response

CFO provided detailed breakdown: garment sharing reducing amortization, automated sortation improving production, SmartTruck reducing routes and idling.

ECLEcolab5 questions · 5 reporting periods · 0 of 5 challenging
ECL company page →

Calendar 2026 Q1

the total customers that you expect to approach with the energy surcharge versus how many you've approached today

PricingCost PressureTranscript · FY2026 Q1 →
Show response

Beck confirmed universal surcharge across all customers, businesses, and 172 countries. Started April 1 and progressing well. Objective to be mostly done by end of Q2/early Q3.

Calendar 2025 Q4

Scott, I was wondering if you could talk about the FX rates that are implicit in your EPS guidance raise

Show response

Kirkland guided FX neutral for 2026 (slightly favorable H1, neutral H2). Tax rate up to 20.5-21.5% from 20.2%. Other income headwind of ~$20M from pension assumptions. Beck confirmed net new business at record levels even in challenged businesses like Basic Industries and Paper.

Calendar 2025 Q3

Just wondering if you could just help us understand a little bit about how that top line is affecting that segment's margin performance?

MarginInnovation & R&DTranscript · FY2025 Q3 →
Show response

Beck quantified Water ex Basic Industries and Paper at 4% top line and 15% OI growth. New Pest customer is entirely new (not conversion), attracted by technology after seeing major retailer success. 400K devices deployed, targeting 1M by H1 2026.

Calendar 2025 Q2

do you still expect it to be a 95% year? And maybe what happened in the first half?

Capital AllocationMarginTranscript · FY2025 Q2 →
Show response

Kirkland guided to ~90% FCF conversion for full year, slightly below 95% target due to elevated CapEx at 7%. Q2 FCF up 17% YoY. Q1 had unfavorable YoY comp from cash payment timing.

Calendar 2025 Q1

what do you think the approximate revenue level needs to be in life sciences to deliver something on that order of magnitude?

MarginRevenue GrowthTranscript · FY2025 Q1 →
Show response

Beck declined to specify revenue target but described long-term investments in UK biotech plant, US E1 facility, Asia capacity, SAP platform, and R&D.

Challenge rate by company

Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.

CompanyQuestionsChallenge rate
J Jacobs Solutions1527%4 of 15 questions
CTAS Cintas80%none of 8 questions
ECL Ecolab50%none of 5 questions
  • J
    Jacobs Solutions · 15 questions
    27%4 of 15 questions
  • CTAS
    Cintas · 8 questions
    0%none of 8 questions
  • ECL
    Ecolab · 5 questions
    0%none of 5 questions

Activity by reporting period

Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.

Questions by calendar reporting period
Calendar periodQuestionsChallenge rateCompanies
2024 Q3250%1 of 2 questions1
2024 Q4425%1 of 4 questions2
2025 Q130%none of 3 questions2
2025 Q230%none of 3 questions2
2025 Q3520%1 of 5 questions3
2025 Q4520%1 of 5 questions3
2026 Q130%none of 3 questions2
2026 Q210%none of 1 question1
2026 Q320%none of 2 questions1
  1. 2024 Q32 questions · challenge rate 50% (1 of 2 questions) · 1 company
  2. 2024 Q44 questions · challenge rate 25% (1 of 4 questions) · 2 companies
  3. 2025 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
  4. 2025 Q23 questions · challenge rate 0% (none of 3 questions) · 2 companies
  5. 2025 Q35 questions · challenge rate 20% (1 of 5 questions) · 3 companies
  6. 2025 Q45 questions · challenge rate 20% (1 of 5 questions) · 3 companies
  7. 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
  8. 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
  9. 2026 Q32 questions · challenge rate 0% (none of 2 questions) · 1 company

Topics

Topics tagged on this analyst’s questions.

  • Margin13
  • M&A7
  • Capital Allocation6
  • Cost Pressure5
  • Demand5
  • Competitive Dynamics4
  • Revenue Growth3
  • Innovation & R&D2
  • Pricing2
  • Regulation Policy2
Show all 13 topics
  • Guidance Reliability1
  • Capex Investment1
  • Fx1